ReviewNeuroscience applied2026
The potential of neuromelanin-sensitive MRI in psychiatric disorders.
Review in Neuroscience applied, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychiatric disorders represent a significant public health concern due to their high prevalence and lifelong substantial impact. Despite advances in understanding their neurobiological underpinnings, the transdiagnostic mechanisms driving psychiatric conditions remain unclear. Neuromelanin-sensitive magnetic resonance imaging (NM-MRI) is a non-invasive technique for investigating the dopaminergic and noradrenergic systems, offering valuable insights into their role in psychiatric disorders. This review explores the potential of NM-MRI in psychiatric research, considering its promise to reveal links between dopaminergic and noradrenergic dysregulation and psychiatric conditions, thereby offering insights in neurobiological mechanisms. We summarize current NM-MRI findings across psychiatric disorders, including psychosis, mood disorders, and anxiety disorders. Across studies, NM-MRI provides converging evidence for alterations in catecholaminergic systems in several psychiatric conditions, particularly schizophrenia, substance use disorders, and depression. However, the evidence base remains uneven, with relatively few studies concerning anxiety disorders, obsessive compulsive disorder, and neurodevelopmental disorders, despite their known associations with dopaminergic and noradrenergic dysfunction. At present, most NM-MRI findings derive from cross-sectional studies using heterogeneous acquisition and analysis approaches, which limits direct comparability and clinical translation. To fully establish NM-MRI as a clinical research tool in psychiatric context, further efforts are needed to standardize protocols and improve specificity and reliability. Moreover, longitudinal studies and cross-diagnostic comparisons are required to determine whether NM-MRI measures can contribute to risk stratification, treatment monitoring, or other clinically applications. Overall, NM-MRI represents a valuable research tool for probing catecholaminergic involvement in psychiatric disorders and may, with further validation, contribute to future biomarker development in mental health research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.